NICE Ltd. NICE ← Back to all reports

NICE Ltd.

NICE · Technology
S ★★★★★ Strong Buy
Aug 15, 2026 · Score 100 · Type A — Value-style analysis Used for established, cash-generative companies — weighs earnings power, valuation against the company's own history and peers, and margin of safety. Full methodology →
Current PriceThe market price around the time this report was written — not a live quote. The market has moved since; check a current price before acting.Methodology → $105.25
Buy ZoneThe large figure is the midpoint of the suggested buy range shown in parentheses. $105.00 ($95.00–$115.00)
Price TargetOur estimated fair value. For richly valued stocks it can sit below the current price — see Methodology.Methodology → $156.38
Expected Return
  • Target relative to the Current Price ((Target − Current) ÷ Current). Since that price is from the report date, your actual return will differ.
  • A negative figure isn't an error. For richly valued stocks, the fair-value target can sit below the current price, so the return reads negative. The grade reflects company quality; this figure reflects today's entry valuation.
Methodology →
+48.6%

Type A - NICE Ltd. (NICE) 20260815 Stock Analysis

📅 NICE Key Upcoming Events

🏢 Step 1: NICE Company Overview & Business Model

Q1-A1. What is NICE?

Q1-A2. How Does NICE Make Money?

Q1-A3. NICE’s Revenue Segments & Core Income Sources

Q1-A4. Who Are NICE’s Competitors?

Q1-A5. NICE Key Events: Past 12 Months

Q1-A6. Step 1 Key Takeaways

🏰 Step 2: NICE’s Economic Moat, Growth & Capital Allocation

Q2-A1. Does NICE Have a Durable Economic Moat?

Q2-A2. Is NICE’s Growth Sustainable?

Q2-A3. How Does NICE Allocate Capital & Return Cash?

Q2-A4. Step 2 Key Takeaways

💰 Step 3: Is NICE Profitable? Financial Health Analysis

Q3-A2. How Profitable Is NICE? (Margins & ROIC)

Q3-A3. What Drives NICE’s Returns? (ROIC Breakdown)

Q3-A4. Are NICE’s Earnings High Quality?

Q3-A5. Is NICE’s Balance Sheet Healthy? (Debt & Leverage)

Q3-A6. Step 3 Key Takeaways

🔎 Step 4: NICE Forensic Accounting & Dilution Review

Q4-A1. Does NICE Have Accounting Red Flags?

Q4-A2. Is NICE Overspending? (Capex & Capital Cycle)

Q4-A3. How Sound Is NICE’s Cash Flow?

Q4-A4. Is NICE Diluting Shareholders?

Q4-A5. Data Integrity Check

Q4-A6. Step 4 Key Takeaways

👔 Step 5: NICE Management & Shareholder Alignment

Q5-A1. Can You Trust NICE’s Management? (Guidance Track Record)

Q5-A2. What Are NICE Insiders Doing?

Q5-A3. Is NICE’s Management Aligned With Shareholders?

Q5-A4. Step 5 Key Takeaways

⛵ Step 6: NICE Market Flow & Sentiment

Q6-A1. Analyst Consensus vs NICE Guidance

Q6-A2. What Is NICE’s Short Interest?

Q6-A3. Step 6 Key Takeaways

🚀 Step 7: NICE Catalysts & Price Triggers

Q7-A1. What Could Move NICE Stock? (Top 3 Catalysts)

Q7-A2. NICE’s Earnings Revision Trend

Q7-A3. Step 7 Key Takeaways

⚖️ Step 8: Is NICE Fairly Valued? Valuation Analysis

Q8-A1. NICE’s Key Valuation Multiples (P/E, EV/EBITDA)

Q8-A2. NICE vs Peers: Valuation Comparison

Q8-A3. Is NICE Cheap or Expensive vs Its History?

Q8-A4. What Growth Is Priced Into NICE? (Reverse DCF)

Q8-A4-1. What Growth Hurdle Does the Market Demand From NICE? (Reverse DCF Alternative)

Q8-A5. Valuation Cross-Check

Q8-A6. NICE’s Hidden Asset & Stake Valuation

Q8-A7. Final Valuation Adjustment

Q8-A8. Valuation Adjustment Score Calculation

💀 Step 9: What Are the Risks of NICE? Fatal Risks & Pre-Mortem

Q9-A1. What Are the Biggest Risks to NICE?

Q9-A2. How Sensitive Is NICE to the Economy?

Q9-A3. NICE Pre-Mortem: What Could Go Wrong?

Q9-A4. Risk Adjustment Score

🎯 Step 10: NICE Final Verdict: Score & Rating

Q10-A1. Investment Score & Rating

Q10-A2. Should You Buy NICE? (Recommendation)

Q10-A3. Investment Thesis in One Line

Q10-A4. NICE’s Price Trend & Key Drivers

Q10-A5. Action Plan

🕵️‍♂️ Deep Dive Analysis

Q1: Is NICE’s Reliance on Seat-Based Pricing Its Biggest Weakness?

Q2: Can NICE’s 9.42x Forward P/E Be Justified by the Generative AI Threat?

Q3: How Does the $955 Million Cognigy Acquisition Alter the CXone Architecture?

Q4: Will Salesforce’s Agentforce Destroy NICE’s Core CCaaS Moat?

Q5: What Is Causing the Brutal Timing Lag Between AI Bookings and Recognized Revenue?

Q6: Can CEO Scott Russell Successfully Navigate the Structural Pivot?

Q7: Why Is the Financial Crime and Compliance Segment Crucial to the Thesis?

Q8: Will the EU AI Act Strangle NICE’s International Growth?

Q9: How Does the RingCentral Partnership Protect Market Share?

Q10: Is the $489 Million Share Buyback the Ultimate Valuation Floor?